Development Initiatives Sample Clauses

Development Initiatives. TiVo may request, in writing, quality improvements and other enhancements to the TMS Licensed Data. TMS agrees to respond in writing to each request with a high-level scope document within [*] of receipt of the initial request, plus the number of days it takes for TiVo to respond to TMS questions. If multiple requests are made in tandem or succession, TMS response times will be [*] per request. If TMS determines that a given request cannot be adequately scoped within the given timeframe due to its size or complexity, TMS agrees to submit a draft scope within the given timeframe that includes the delivery date for the final scope document. Each scope document will outline the feasibility, recommended approach, and a good faith estimate of the timeframe for implementing a given request. TiVo agrees to respond to TMS questions, in writing, within 5 business days. After TiVo receives a scope document, TiVo may request in writing that TMS proceed with the development initiative. TMS, in turn, will use commercially reasonable efforts to implement such requests that are reasonably feasible. Prior to TMS commencing work on a development initiative, the parties will work cooperatively to define acceptance standards and the scope of the project in writing. If the initiative solely benefits TiVo, then development and licensing fees will be negotiated in good faith between TiVo and TMS; otherwise, development will be completed at no cost TiVo. TiVo hereby requests the development initiatives set forth in Exhibit B. TMS will provide scope documents for the [*] within [*] after the Effective Date, plus the number days it takes for TiVo to respond to TMS questions. TMS will use commercially reasonable efforts to implement the [*] from Exhibit B [*] from the Effective Date and the rest of the development initiatives will be completed [*] from the Effective Date. Thereafter, TiVo may request in writing [*] development initiatives each year from the Effective Date. During the scoping phase, TMS will provide cost estimates to TiVo for the implementation of these requests. TMS will incur a maximum of [*] in development costs at no charge to TiVo for each twelve month period from the Effective Date (“Development Cost Commitment”). TiVo and TMS will reasonably cooperate to negotiate any costs that exceed [*]. TMS will use best efforts to deliver products to TiVo in the amount of time TMS scoped. [*]. [*] Certain information on this page has been omitted and filed separately wit...
Sample 1
AutoNDA by SimpleDocs
Development Initiatives 
Sample 1Sample 2

Related to Development Initiatives

  • Research Neither the Investor nor any Affiliate of the Investor shall have, in the prior thirty (30) days, published or distributed any research report (as such term is defined in Rule 500 of Regulation AC) concerning the Company.

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development Activities NovaDel shall not be required to commence any Development Activities until Licensee has paid at least twenty-five percent (25%) of the non-refundable License Fee described in Section 4.4.

  • Development 3.1.1 Licensee agrees to and warrants that:

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Projects 3.3.1 Exult Supplier shall perform the impact analysis as described in Section 4.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Development Work Do, or cause to be done, such development and other work as may be reasonably necessary to protect from diminution and production capacity of the Mortgaged Property and each producing well thereon.

Time is Money Join Law Insider Premium to draft better contracts faster.